Award

PICCOS TRIAL

  • NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

F15: Voluntary ex ante transparency notice

Notice identifier: 2023/S 000-013430

Procurement identifier (OCID): ocds-h6vhtk-03c7e6

Published 11 May 2023, 11:35am



Section one: Contracting authority/entity

one.1) Name and addresses

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw

Cardiff

CF15 7QZ

Email

rhodri.poacher@wales.nhs.uk

Telephone

+44 1443848585

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

http://nwssp.nhs.wales/ourservices/procurement-services/

Buyer's address

https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

PICCOS TRIAL

Reference number

CAV-STA (22-23) 212

two.1.2) Main CPV code

  • 79314000 - Feasibility study

two.1.3) Type of contract

Services

two.1.4) Short description

This trial aims to determine if a new way of delivering chemotherapy as a spray, directly into the peritoneal cavity, might improve survival in patients with peritoneal metastases, compared to conventional intravenous chemotherapy.

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £1,974,920.41

two.2) Description

two.2.2) Additional CPV code(s)

  • 79314000 - Feasibility study

two.2.3) Place of performance

NUTS codes
  • UKL22 - Cardiff and Vale of Glamorgan
Main site or place of performance

University Hospital of Wales.

two.2.4) Description of the procurement

Bowel, ovarian and stomach cancer often spreads to the lining of the abdominal cavity. This trial aims to determine if a new way of delivering chemotherapy as a spray, directly into the peritoneal cavity, might improve survival in patients with peritoneal metastases, compared to conventional intravenous chemotherapy. Critically, we will also assess the impact of treatment on patient quality of life.

Up to 13%, 50% and 14% of patients with bowel, ovarian and stomach cancer respectively, present with

peritoneal metastases. When this form of spread occurs, patients are normally told their disease is

incurable. As well as a relatively rapid decline, peritoneal metastases can cause a series of unpleasant

symptoms due to new tumour growth. Peritoneal metastases are difficult to treat with conventional anticancer drugs and there is an urgent need to develop new treatment strategies. A new strategy showing

potential is Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC). PIPAC delivers anti-cancer

drugs into the peritoneal cavity as an aerosol during keyhole surgery. PIPAC has been shown to deliver

higher doses of chemotherapy directly to tumour sites compared to conventional treatment, with fewer

side-effects due to less chemotherapy circulating in the blood. PIPAC has been shown to be both safe and feasible in a series of clinical trials. The question that now remains is whether PIPAC is efficacious

or not.

PIPAC has excited much interest in patient groups. CAV will disseminate study results through social

media, relevant charitable organisations, presentation at academic conferences, peer-reviewed journals

as well as through the trial web page hosted at the Centre for Trials Research. Information leaflets,

public presentations and media coverage are integral elements of our public engagement plans. The

results will strongly influence a future NICE review of PIPAC in the UK.

two.2.11) Information about options

Options: No

two.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

  • The procurement falls outside the scope of application of the regulations

Explanation:

This contract will be awarded to the Cardiff University, who have senior personnel with a large amount of experience in this area of research who are leading on this research project.

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes


Section five. Award of contract/concession

Contract No

CAV-STA (22-23) 212

A contract/lot is awarded: Yes

five.2) Award of contract/concession

five.2.1) Date of conclusion of the contract

11 May 2023

five.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor/concessionaire

CARDIFF UNIVERSITY

CARDIFF UNIVERSITY, 30 36 NEWPORT ROAD

CARDIFF

CF240DE

Country

United Kingdom

NUTS code
  • UK - United Kingdom
The contractor/concessionaire is an SME

No

five.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £1,974,920.41


Section six. Complementary information

six.3) Additional information

This VEAT will be in place for 10 calendar days from 11th May 2023 until 22nd May 2023.

NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=131480.

(WA Ref:131480)

six.4) Procedures for review

six.4.1) Review body

High Court

Royal Courts of Justice, The Strand

London

WC2A 2LL

Telephone

+44 2079477501

Country

United Kingdom